Dynavax Technologies Target of Unusually Large Options Trading (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) was the target of unusually large options trading activity on Tuesday. Traders acquired 3,017 call options on the company. This is an increase of approximately 803% compared to the typical daily volume of 334 call options.

Hedge Funds Weigh In On Dynavax Technologies

Several large investors have recently modified their holdings of DVAX. Deep Track Capital LP increased its stake in Dynavax Technologies by 42.0% during the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock valued at $227,197,000 after purchasing an additional 5,265,000 shares in the last quarter. Deerfield Management Company L.P. Series C lifted its stake in Dynavax Technologies by 23,990.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock valued at $66,325,000 after acquiring an additional 5,172,263 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Dynavax Technologies by 4.4% during the 4th quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock valued at $51,948,000 after acquiring an additional 171,933 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Dynavax Technologies by 1.8% in the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company’s stock worth $30,077,000 after acquiring an additional 41,000 shares during the period. Finally, D. E. Shaw & Co. Inc. raised its holdings in shares of Dynavax Technologies by 34.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock valued at $24,497,000 after purchasing an additional 486,981 shares during the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on DVAX. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. Finally, The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and dropped their price target for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th.

Dynavax Technologies Stock Up 0.8 %

Shares of NASDAQ:DVAX traded up $0.12 during trading on Tuesday, hitting $13.96. The stock had a trading volume of 167,836 shares, compared to its average volume of 1,994,832. The company has a market capitalization of $1.73 billion, a PE ratio of 77.53 and a beta of 1.23. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. The firm’s fifty day moving average is $13.24 and its 200 day moving average is $12.43. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.05. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. The business had revenue of $72.03 million during the quarter, compared to the consensus estimate of $72.70 million. Analysts anticipate that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.